As of 11:06 on February 6, the Shanghai Composite Index gained 0.14%, the Shenzhen Component Index rose 0.58%, and the ChiNext Index advanced 0.57%. Leading the gains were sectors such as glyphosate, fluorochemical concepts, and propylene oxide. Among ETFs, the Hong Kong Innovative Drug ETF (159567) increased by 1.18%. Constituent stocks including InnoCare Pharma (09969.HK) surged over 10%, while United Laboratories (03933.HK) climbed more than 5%. Other gainers included Simcere Pharmaceutical (02096.HK), Keymed Biosciences (02162.HK), Lepu Biopharma (02157.HK), Kelun-Biotech (06990.HK), CMS Pharma (00867.HK), CanSino Biologics (688185.SH), Innovent Biologics (01801.HK), and Ascentage Pharma (06855.HK).
The momentum for Chinese innovative drugs expanding overseas has continued to intensify since the beginning of 2026, with domestic pharmaceutical companies such as RemeGen securing significant overseas licensing deals. Concurrently, multiple government bodies including the National Healthcare Security Administration and the National Medical Products Administration have been collaborating to strengthen policy and platform support for the global expansion of pharmaceuticals and medical devices.
Shanghai Securities noted a significant rise in the number of people with dyslipidemia in China in recent years, highlighting progress in metabolic disease areas such as PCSK9 targets and small nucleic acid therapies. According to the "Chinese Guideline on Lipid Management (2023)", patients with dyslipidemia are categorized into low-risk, moderate-risk, high-risk, very high-risk, and extremely high-risk groups based on their ASCVD risk stratification, each with corresponding LDL-C target levels. Current common lipid-lowering regimens have certain limitations in clinical practice, often making it difficult for patients to achieve long-term, stable lipid control. Over recent decades, blood lipid levels and the prevalence of dyslipidemia in the Chinese population have increased markedly, with hypercholesterolemia showing the most significant rise. The number of individuals with dyslipidemia in China now exceeds 400 million, with a trend toward younger onset.
Bohai Securities indicated that the pharmaceutical and biological sector experienced volatile performance in January, starting with a strong rally driven by hotspots like brain-computer interfaces, small nucleic acids, and AI applications, followed by a sector adjustment. The J.P. Morgan Healthcare Conference held from January 12-15, 2026, in San Francisco featured numerous Chinese pharmaceutical companies showcasing their latest research findings and advancements. Recent substantial business development deals and active collaborations with multinational corporations further demonstrate the robust R&D capabilities of China's innovative drug sector. The firm recommends seizing investment opportunities in related industry chains such as innovative drugs, CXO, and the upstream life sciences sector, while also paying attention to niche segments like small nucleic acids. Additionally, as the earnings preview season begins, attention should be given to companies showing signs of a bottom-line recovery. Meanwhile, the rapid development of brain-computer interfaces and AI applications presents layout opportunities for related enterprises.